

1. Please replace claim 1 with amended claim 1:

- Sub D1*
C1
1. A chimeric peptide comprising a μ opioid receptor binding moiety at its N-terminus and an agonist Substance P receptor binding moiety at its C-terminus, wherein said peptide induces analgesia.

2. Please replace claim 28 with amended claim 28:

- C2*
28. The peptide of claim 1, wherein said opioid receptor binding moiety is a μ receptor agonist. *ID*

3. Please replace claims 31-33 with amended claims 31-33:

- Sub D1*
31. The peptide of claim 30 wherein said opioid receptor binding moiety is a peptide having any one of SEQ ID Nos: 1-11, or an N-terminal fragment or N-terminal derivative thereof.
- C3*
32. The peptide of claim 30 wherein said opioid receptor binding moiety is endomorphin 1, endomorphin 2, an N-terminal fragment, or an N-terminal derivative thereof.
33. The peptide of claim 32 wherein said opioid receptor binding moiety is a peptide having SEQ ID No: 2 or 3, or an N-terminal fragment or N-terminal derivative thereof.

4. Please replace claims 45 and 46 with amended claims 45 and 46:

- Sub D1*
C4
45. The peptide of claim 1, wherein said agonist Substance P receptor binding moiety comprises Substance P, a C-terminal Substance P fragment, or a C-terminal Substance P derivative.
46. The peptide of claim 1, wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is protected.

5. Please replace claim 49 with amended claim 49:

- Sub D1* *C5* 49. The peptide of claim 48 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 21, 36 and 38-41, or a C-terminal fragment or C-terminal derivative thereof.

6. Please replace claim 53 with amended claim 53:

- C6* 53. The peptide of claim 52 wherein said Substance P receptor binding moiety is a peptide having any one of ~~SEQ~~ SEQ ID Nos: 25-27, or a C-terminal fragment or C-terminal derivative thereof.

7. Please replace claims 56 and 57 with amended claims 56 and 57:

56. The peptide of claim 55 wherein said Substance P receptor binding moiety is a peptide having any one of ~~SEQ~~ SEQ ID Nos: 28-30, or a C-terminal fragment or C-terminal derivative thereof.

- C7* *Sub D1* 57. The peptide of claim 1 wherein the opioid receptor binding moiety is endomorphin 1, endomorphin 2, or an N-terminal fragment or N-terminal derivative thereof; and the Substance P receptor binding moiety is Substance P, or a C-terminal fragment or C-terminal derivative thereof.

8. Please replace claim 61 with amended claim 61:

- C8* 61. The peptide of ~~claim~~ claim 1 wherein said peptide comprises at least one D-amino acid.

9. Please replace claim 64 with amended claim 64:

- Sub D1* *C8* 64. The pharmaceutical composition of claim 62, wherein said peptide induces analgesia when administered to a mammal.

10. Please replace claims 69-74 with amended claims 68-74:

69. The pharmaceutical composition of claim 62, wherein said opioid receptor binding moiety is a μ receptor agonist.
70. The pharmaceutical composition of claim 69 wherein the N-terminal amino acid residue of said opioid receptor binding moiety is a free amine.
71. The pharmaceutical composition of claim 70 wherein the N-terminal amino acid residue of said opioid receptor binding moiety is Tyr.
72. The pharmaceutical composition of claim 71 wherein said opioid receptor binding moiety is a peptide having any one of SEQ ID Nos: 1-11, or an N-terminal fragment or N-terminal derivative thereof.
73. The pharmaceutical composition of claim 71 wherein said opioid receptor binding moiety is endomorphin 1, endomorphin 2, an N-terminal fragment, or an N-terminal derivative thereof.
74. The pharmaceutical composition of claim 73 wherein said opioid receptor binding moiety is a peptide having SEQ ID No: 2 or 3, or an N-terminal fragment or N-terminal derivative thereof.

11. Please replace claims 86-100 with amended claims 86-100:

86. The pharmaceutical composition of claim 62, wherein said agonist Substance P receptor binding moiety comprises Substance P, a C-terminal Substance P fragment, or a C-terminal Substance P derivative.

87. The pharmaceutical composition of claim 62, wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is protected.
88. The pharmaceutical composition of claim 87 wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is amidated.
89. The pharmaceutical composition of claim 88 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is Met-NH₂.
90. The pharmaceutical composition of claim 89 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 21, 36 and 38-41, or a C-terminal fragment or C-terminal derivative thereof.
91. The pharmaceutical composition of claim 87 wherein the -COOH moiety of the C-terminal amino acid residue of said Substance P receptor binding moiety is esterified.
92. The pharmaceutical composition of claim 91 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is a methyl ester.
93. The pharmaceutical composition of claim 92 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is Gly-OMe, Lys-COOMe or Arg-COOMe.
94. The pharmaceutical composition of claim 93 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 25-27, or a C-terminal fragment or C-terminal derivative thereof.
95. The pharmaceutical composition of claim 91 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is an ethyl ester.

96. The pharmaceutical composition of claim 95 wherein the C-terminal amino acid residue of said Substance P receptor binding moiety is Gly-COOEt, Lys-COOEt or Arg-COOEt.
97. The pharmaceutical composition of claim 96 wherein said Substance P receptor binding moiety is a peptide having any one of SEQ ID Nos: 28-30, or a C-terminal fragment or C-terminal derivative thereof.
98. The pharmaceutical composition of claim 62 wherein the opioid receptor binding moiety is endomorphin 1, endomorphin 2, or an N-terminal fragment or N-terminal derivative thereof; and the Substance P receptor binding moiety is Substance P, or a C-terminal fragment or C-terminal derivative thereof.
99. The pharmaceutical composition of claim 62 wherein the peptide has SEQ ID No: 42.
100. The pharmaceutical composition of claim 62 wherein the peptide has SEQ ID No: 43.

12. Please replace claim 102 with amended claim 102:

102. The pharmaceutical composition of claim 62 wherein said peptide comprises at least one D-amino acid.

REMARKS

Claims 1, 2 and 24-102 are currently pending in the subject application. Claims 34-44, 53, 56, 75-85, 94 and 97 have been withdrawn from consideration by the Examiner as being drawn to a non-elected invention (*i.e.*, delta and kappa opioid receptor binding moieties). The Examiner has further withdrawn claims 58, 59, 99 and 100 from consideration based on election by original presentation. The Examiner further rejected claims 1, 2, 24-26, 31, 33, 45-52, 54, 55, 60-67, 72, 74, 86-93, 95, 96, 101 and 102 for encompassing non-elected subject matter. In